CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 14,915	$ 11,503	$ 44,099	$ 61,549
General and administrative	2,940	3,330	9,833	10,672
Total operating expenses	17,855	14,833	53,932	72,221
Loss from operations	(17,855)	(14,833)	(53,932)	(72,221)
Interest income	894	1,084	2,534	3,089
Australian research and development incentives	(499)	554		1,124
Foreign currency loss	(8)	(501)	(18)	(953)
Change in fair value of Series X preferred stock warrant liability				12
Loss before income taxes	(17,468)	(13,696)	(51,416)	(68,949)
Provision for income taxes	(708)		(708)
Net loss	(18,176)	(13,696)	(52,124)	(68,949)
Dividend attributable to down round feature of warrants			(234)
Net loss attributable to common stockholders	$ (18,176)	$ (13,696)	$ (52,358)	$ (68,949)
Net loss per share
Basic (in dollars per share)	$ (0.44)	$ (0.51)	$ (1.44)	$ (3.78)
Diluted (in dollars per share)	$ (0.44)	$ (0.51)	$ (1.44)	$ (3.78)
Weighted average common shares outstanding
Basic (in shares)	41,209,639	26,987,182	36,307,890	18,240,455
Diluted (in shares)	41,209,639	26,987,182	36,307,890	18,240,455